Hemoglobin microparticles and artificial oxygen carriers
Core-shell hemoglobin microparticles with crosslinked hemoglobins and mercapto group-coated shells address the challenges of biocompatibility and stability in artificial oxygen carriers, providing effective and safe oxygen transport.
Patent Information
- Application Number
- JP2020034372
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-02-28
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-02-28
AI Technical Summary
Existing artificial oxygen carriers face challenges such as potential side effects, limited effectiveness, and difficulty in maintaining stability and biocompatibility, particularly due to issues with particle size and retention in the bloodstream, which can lead to liver dysfunction and reduced efficacy.
The development of core-shell type hemoglobin microparticles, where a core of crosslinked hemoglobins is coated with shell molecules containing mercapto groups, allowing for controlled particle size and improved biocompatibility through specific bonding of maleimide and mercapto groups, preventing passage through liver sinusoidal pores and enhancing retention.
The resulting hemoglobin microparticles are highly biocompatible, safe, and easy to produce, offering stable oxygen transport capabilities without causing liver dysfunction, with enhanced retention in the bloodstream and reduced immunogenicity.
Smart Images

Figure 0007593609000029 
Figure 0007593609000030 
Figure 0007593609000031
Abstract
Description
[Technical field]
[0001] The present invention relates to hemoglobin microparticles and artificial oxygen carriers. [Background technology]
[0002] When a large amount of blood is lost due to an accident, disaster, or even surgery, it is necessary to administer a blood transfusion as soon as possible to restore the body's oxygen transport function. First, the priority is given to restoring the circulating blood volume by infusing saline solution, etc., but since red blood cells are responsible for oxygen transport among the blood components, administration of red blood cell preparations is extremely important. Red blood cells (major axis: about 8 micrometers) contain about 250 million hemoglobin molecules (heme protein with oxygen binding capacity and molecular weight of about 64,500, which has heme as the active center) at a high concentration of about 35%. After binding oxygen in the lungs, the hemoglobin in the red blood cells releases oxygen in the periphery and supplies oxygen to the body's tissue cells. In many medically advanced countries, blood donation and transfusion systems are in place, so transfusion treatment can be performed without any problems in medical facilities where red blood cell preparations are stored or in areas where red blood cell preparations can be transported in a short time. Since virus tests have also been completed, there is almost no risk of infection with known viruses associated with blood transfusions. However, there are also universal problems inherent in transfusion therapy (especially administration of red blood cell products), and the following are some of the specific concerns: (1) It takes about 40 minutes to check the blood type (cross-match) before administering red blood cell products, so emergency patients may not be able to receive them in time. (2) Red blood cells can only be stored for 21 days at 4°C, so they cannot be stockpiled for a long period of time. Therefore, in the event of a large-scale disaster or earthquake that results in a large number of patients at once, even if a large amount of blood is needed for transfusion at once, it is not possible to secure a sufficient amount. (3) It is impossible to completely eliminate the risk of infection with unknown viruses. Furthermore, serious problems are expected to occur as social conditions change in the future. (4) If the declining birthrate and aging population accelerates, the number of elderly people who need blood transfusions will continue to increase, and the number of young blood donors will decrease, it will become difficult to even provide a stable supply of blood transfusions in normal medical care. Given the above background, there is currently great hope for the development of artificial blood, especially artificial oxygen carriers that can serve as a substitute for red blood cells.
[0003] Since the 1980s, efforts have been made, primarily in Europe, the United States, and Japan, to develop artificial oxygen carriers that have no blood type (and therefore can be used with all blood types), are free of the risk of viral or bacterial infection, can be stored for long periods, and can be used whenever and wherever necessary. For example, in Japan, a cell-type artificial oxygen carrier has been developed in which hemoglobin is encapsulated in the internal aqueous phase of a bilayer membrane vesicle (liposome) formed by the self-organization of phospholipid molecules in water (see, for example, Patent Document 1). This cell-type artificial oxygen carrier has no significant side effects and is eagerly awaited for practical use, but has not yet reached clinical trials due to the need for advanced preparation techniques, high initial costs, etc. Meanwhile, in the United States, artificial oxygen carriers such as intramolecularly crosslinked hemoglobin (see, for example, Patent Document 2), hemoglobin polymers in which human hemoglobin is bound with a crosslinking agent (see, for example, Patent Document 3), hemoglobin polymers in which bovine hemoglobin is bound with a crosslinking agent (see, for example, Patent Document 4), and polyethylene glycol-bound hemoglobin in which polyethylene glycol, a water-soluble polymer, is bound to the molecular surface of human hemoglobin (see, for example, Patent Document 5) have been developed and clinical trials have been conducted. These artificial oxygen carriers are designed to have a structure that avoids renal excretion of hemoglobin by crosslinking between subunits or increasing the molecular size (molecular weight). However, there are no formulations approved by the Food and Drug Administration (FDA) for reasons such as side effects such as increased blood pressure due to vasoconstriction and cardiotoxicity, and little difference in effect between the artificial oxygen carrier administration group and the physiological saline administration group. The present inventors have also synthesized an artificial oxygen carrier in which human serum albumin, a plasma protein, is bound to the molecular surface of hemoglobin, i.e., a (hemoglobin-albumin) cluster, and have revealed that it functions as a red blood cell substitute with excellent safety and effectiveness (see, for example, Patent Document 6). Currently, evaluation tests are being conducted for practical use. This (hemoglobin-albumin) cluster has attracted attention as a highly feasible preparation, but it has also been found that improving the molecular size is important to make it an even more ideal artificial oxygen carrier. Since the particle size of the (hemoglobin-albumin) cluster is 15 nm, it may pass through small holes (pore diameter about 50 to 150 nm) in the sinusoidal endothelial cells in the liver and gradually diffuse into the extrasinusoidal space. If carbon monoxide, a vasorelaxant, is captured by the leaked (hemoglobin-albumin) cluster, it may cause sinusoidal vascular contraction, which may cause liver dysfunction. In other words, it is preferable that the (hemoglobin-albumin) cluster has a particle size that makes it difficult for it to pass through small holes in sinusoidal endothelial cells, and this is also expected to prolong retention in the blood. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] JP 2004-307404 A [Patent Document 2] Japanese Patent Application Publication No. 10-306036 [Patent Document 3] Special Publication No. 11-502821 [Patent Document 4] Special Publication No. 2006-516994 [Patent Document 5] Special Publication No. 2005-515225 [Patent Document 6] Patent No. 6083674 Summary of the Invention [Problem to be solved by the invention]
[0005] Therefore, an object of the present invention is to provide hemoglobin microparticles and an artificial oxygen carrier that are highly biocompatible, highly safe, and easy to prepare (synthesize). [Means for solving the problem]
[0006] The hemoglobin microparticles of the present invention are core-shell type hemoglobin microparticles, and are characterized in that they comprise a core microparticle containing multiple hemoglobins cross-linked to each other, and a shell material covering at least a portion of the surface of the core microparticle and containing multiple shell molecules having mercapto groups, and the shell molecules are bonded to the core microparticle by the mercapto groups.
[0007] In the hemoglobin microparticles of the present invention, it is desirable that a maleimide group is introduced onto the molecular surface of the hemoglobin, that the hemoglobin is crosslinked via a crosslinking molecule having two or more mercapto groups, and that the maleimide group of the hemoglobin is bonded to the mercapto group of the crosslinking molecule.
[0008] In the hemoglobin microparticles of the present invention, it is desirable that the site in the hemoglobin to which the maleimide group is introduced is a lysine and / or a primary amine at the protein terminal.
[0009] In the hemoglobin microparticles of the present invention, the maleimide group of the hemoglobin is derived from a maleimide group introduction agent, and the maleimide group introduction agent is desirably a compound represented by the following general formula (1). [ka] (In the general formula (1), R2 is a hydrogen atom or SO3 - Na + wherein R1 represents either the following general formula (2) or (3) or the following chemical formula (1) or (2). [ka] (In general formula (2), n represents an integer of 1 to 10.) [ka] [ka] [ka] (In the general formula (3), n represents an integer of 2, 4, 6, 8, 10, or 12.)
[0010] In the hemoglobin microparticles of the present invention, the crosslinking molecule having two or more mercapto groups is desirably at least one selected from the group consisting of a bifunctional compound having mercapto groups at both ends (dithiothreitol, dithioerythritol, dimercaptosuccinic acid, or a compound having a weight-average molecular weight in the range of 180 to 20,000 daltons and represented by the following general formula (4)) or a mercapto group-introduced hemoglobin in which two or more mercapto groups have been introduced into lysines on the molecular surface and / or primary amines at the protein terminals. [ka] (In general formula (4), n represents an integer of 1 to 450.)
[0011] In the hemoglobin microparticles of the present invention, it is desirable that the hemoglobin constituting the core microparticle comprises at least one type selected from the group consisting of human hemoglobin, bovine hemoglobin, equine hemoglobin, porcine hemoglobin, rabbit hemoglobin, canine hemoglobin, feline hemoglobin, recombinant hemoglobin, recombinant hemoglobin mutants, and intramolecularly crosslinked hemoglobin.
[0012] In the hemoglobin microparticles of the present invention, it is desirable that the hemoglobin constituting the core microparticle has a maleimide group introduced to a primary amine at the lysine and / or protein terminal, and that the binding site of the core microparticle with the shell molecule having the mercapto group is the maleimide group introduced to the primary amine at the lysine and / or protein terminal.
[0013] In the hemoglobin microparticles of the present invention, it is desirable that the shell molecule having a mercapto group contains at least one kind selected from the group consisting of proteins having a mercapto group, specifically, human serum albumin, bovine serum albumin, horse serum albumin, porcine serum albumin, rabbit serum albumin, canine serum albumin, feline serum albumin, recombinant albumin, recombinant albumin mutants, compounds having a weight-average molecular weight in the range of 500 to 100,000 daltons and represented by the following general formulas (5) to (7), mercaptoethanol, mercapto fatty acid, cysteine, cysteine methyl ester, cysteine ethyl ester, N-acetylcysteine, N-acetylcysteine methyl ester, and homocysteine. [ka] (In general formula (5), n represents an integer of 9 to 2,270.) [ka] (In the general formula (6), n represents an integer of 2 to 1,000, m represents an integer of 1 to 10, and R1 represents any one of a methyl group, an ethyl group, a propyl group, and an isopropyl group.) [ka] (In the general formula (7), n represents an integer of 2 to 1,000, m represents an integer of 1 to 10, and R1 represents any one of a methyl group, an ethyl group, a propyl group, and an isopropyl group.)
[0014] The artificial oxygen carrier of the present invention is characterized by containing the hemoglobin microparticles of the present invention. Effect of the Invention
[0015] According to the present invention, it is possible to provide hemoglobin microparticles and artificial oxygen carriers that are highly biocompatible, highly safe, and easy to prepare (synthesize). [Brief description of the drawings]
[0016] [Figure 1] FIG. 2 is a diagram showing an example of a hemoglobin microparticle according to one embodiment of the present invention. [Diagram 2] 1 is a flowchart showing a method for producing hemoglobin microparticles according to one embodiment of the present invention. [Diagram 3] 1 is a graph showing the oxygen dissociation curves of the hemoglobin microparticles obtained in Examples 1 and 5, and purified bovine hemoglobin (HbBv). [Figure 4] 2 is a graph showing the stability of the hemoglobin microparticles obtained in Example 1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] Below, the form for carrying out the present invention will be specifically illustrated and described with reference to the drawings as necessary. However, the present invention is not limited to the following description, and can be carried out in various modified forms within the scope of the gist thereof.
[0018] <Hemoglobin particles> The hemoglobin microparticles of this embodiment are core-shell type microparticles having a core-shell structure, which includes at least a core microparticle containing a plurality of hemoglobins crosslinked with each other, and a shell material covering at least a part of the surface of the core microparticle and containing a plurality of shell molecules having a mercapto group, and further includes other portions as necessary. The shell molecules having the mercapto group are bonded (covalently bonded) to the core microparticle (the hemoglobin constituting the core microparticle) through the mercapto group.
[0019] 1 is a diagram showing an example of a hemoglobin microparticle of this embodiment. The hemoglobin microparticle 10 is composed of a core microparticle 2 made of a plurality of hemoglobin molecules 1 cross-linked with each other, and a shell material 4 containing a plurality of shell molecules 3 having a mercapto group (mercapto group is not shown). The shell material 4 covers at least a part of the surface of the core microparticle 2, forming a core-shell structure.
[0020] The particle size of the hemoglobin microparticles is preferably 50 to 500 nm because they are unlikely to pass through small pores in sinusoidal endothelial cells in the liver, and considering that they are passed through a sterilizing filter for sterilization during formulation, the particle size is more preferably 50 to 200 nm, and even more preferably 60 to 160 nm. Methods for adjusting the particle size of hemoglobin microparticles include, for example, a method for adjusting the particle size of core microparticles, a method for adjusting the weight-average molecular weight of shell molecules, and the like.
[0021] In the hemoglobin microparticles of the present embodiment, the coverage of the core microparticles with the shell molecules having a mercapto group is not particularly limited, and it is sufficient that at least a part of the core microparticles are covered. The coverage may be appropriately adjusted depending on the size and purpose of the hemoglobin microparticles, but is preferably 60% or more, more preferably 65% or more, and even more preferably 70% or more. In addition, as a method for measuring and calculating the above-mentioned coverage rate, for example, in the case of hemoglobin microparticles having serum albumin as the shell material, a method can be used in which the molar ratio of hemoglobin and serum albumin constituting the hemoglobin microparticles is calculated from the measurement of the circular dichroism (CD) spectrum, and the number of serum albumins constituting the shell material is divided by the number of hemoglobins constituting the surface of the core microparticles.
[0022] [Core particle] The core microparticle contained in the hemoglobin microparticle of this embodiment contains a plurality of hemoglobin molecules that are cross-linked to one another. The crosslinking of hemoglobin is preferably formed by binding a mercapto group of a crosslinking molecule having two or more mercapto groups to a maleimide group introduced to the molecular surface of the hemoglobin by, for example, a maleimide group-introducing agent, etc. In other words, the multiple hemoglobins crosslinked to each other are preferably hemoglobin polymers in which hemoglobin having a maleimide group introduced therein (hereinafter also simply referred to as "maleimide group-introduced hemoglobin") is crosslinked (polymerized) with a crosslinking molecule having two or more mercapto groups. The advantages of a crosslinked structure consisting of maleimide group-introduced hemoglobin and a crosslinking molecule having two or more mercapto groups include high efficiency because the maleimide group selectively binds to the mercapto group, the ability to select a functional molecule having a function other than crosslinking as the crosslinking molecule, and ease of control of the particle size of the hemoglobin microparticles. In addition to a plurality of hemoglobins (hemoglobin polymers) cross-linked to each other, the core microparticles can further bind functional molecules such as functional proteins and drugs depending on the purpose of the hemoglobin microparticles.
[0023] The particle size of the core microparticles is not particularly limited and may be adjusted appropriately depending on the size and purpose of the hemoglobin microparticles. From the viewpoint of obtaining hemoglobin microparticles that do not easily pass through the small pores of sinusoidal endothelial cells in the liver, the particle size is preferably 30 to 480 nm, and from the viewpoint of passing the hemoglobin microparticles through a sterilization filter for sterilization, the particle size is more preferably 30 to 180 nm, and even more preferably 40 to 140 nm.
[0024] [[hemoglobin]] The hemoglobin is composed of four hemoglobin subunits and has a molecular weight of, for example, about 64,500 daltons. Each subunit of hemoglobin has one protoheme. An oxygen molecule binds to an iron atom in the protoheme. That is, one hemoglobin binds to four oxygen molecules.
[0025] The hemoglobin may have at least one hemoglobin subunit bound to another hemoglobin via a cross-linking molecule. For example, all four hemoglobin subunits may have another hemoglobin bound to them via a cross-linking agent, or may include a hemoglobin subunit that is not bound to another hemoglobin via a cross-linking agent. Furthermore, the hemoglobin may have shell molecules having a mercapto group bound to all four hemoglobin subunits, or may include hemoglobin subunits to which no shell molecule having a mercapto group is bound.
[0026] The hemoglobin is not particularly limited, and may be one purified from red blood cells derived from vertebrates including humans, and may be appropriately selected according to the purpose. The hemoglobin may be, for example, human hemoglobin, bovine hemoglobin, equine hemoglobin, porcine hemoglobin, rabbit hemoglobin, canine hemoglobin, or feline hemoglobin. The hemoglobin may also be a recombinant hemoglobin or a recombinant hemoglobin mutant that can be produced by protein synthesis (culture). Furthermore, the hemoglobin may be an intramolecular crosslinked hemoglobin or the like. These may be used alone or in combination of two or more.
[0027] -Human hemoglobin- The human hemoglobin is not particularly limited as long as it is purified from human-derived red blood cells, and can be appropriately selected depending on the purpose.
[0028] -Bovine hemoglobin- The bovine hemoglobin is not particularly limited as long as it is purified from red blood cells derived from bovines, and can be appropriately selected depending on the purpose.
[0029] -Horse hemoglobin- The horse hemoglobin is not particularly limited as long as it is purified from red blood cells derived from a horse, and can be appropriately selected depending on the purpose.
[0030] -Pig hemoglobin- The porcine hemoglobin is not particularly limited as long as it is purified from red blood cells derived from pigs, and can be appropriately selected depending on the purpose.
[0031] -Rabbit hemoglobin- The rabbit hemoglobin is not particularly limited as long as it is purified from red blood cells derived from rabbits, and can be appropriately selected depending on the purpose.
[0032] -Canine hemoglobin- The canine hemoglobin is not particularly limited as long as it is purified from red blood cells derived from dogs, and can be appropriately selected depending on the purpose.
[0033] -Feline hemoglobin- The feline hemoglobin is not particularly limited as long as it is purified from red blood cells derived from a cat, and can be appropriately selected depending on the purpose.
[0034] -Recombinant hemoglobin- The recombinant hemoglobin is not particularly limited as long as it is produced by ordinary gene recombination and culture procedures, and can be appropriately selected depending on the purpose.
[0035] -Recombinant hemoglobin mutants- The recombinant hemoglobin mutant is not particularly limited as long as it is produced by ordinary gene recombination and culture procedures, and can be appropriately selected depending on the purpose.
[0036] -Intramolecularly cross-linked hemoglobin- The intramolecularly crosslinked hemoglobin is not particularly limited and can be appropriately selected depending on the purpose. Examples thereof include hemoglobin in which subunits are bonded to each other via a crosslinking agent. Specific examples of the intramolecularly cross-linked hemoglobin are not particularly limited and can be appropriately selected depending on the purpose. Examples include Diaspirin cross-linked hemoglobin (substance name: DCLHb, Baxter Healthcare).
[0037] [[Maleimide group introduction agent]] The maleimide group-introducing agent is not particularly limited as long as it is a reagent capable of introducing a maleimide group into hemoglobin, and can be appropriately selected according to the purpose. For example, from the viewpoint of reaction efficiency and water solubility, a bifunctional compound represented by the following general formula (1) in which one end is a succinimidyl group (active ester group) and the other end is a maleimide group can be mentioned. These may be used alone or in combination of two or more kinds. [ka] (In the general formula (1), R2 is a hydrogen atom or SO3 - Na + R1 represents either the following general formula (2) or (3) or the following chemical formula (1) or (2). [ka] (In general formula (2), n represents an integer of 1 to 10.) [ka] [ka] [ka] (In the general formula (3), n represents an integer of 2, 4, 6, 8, 10, or 12.)
[0038] The succinimidyl group (active ester group) in the maleimide group-introducing agent forms an amide bond (covalent bond) with the amino group (NH2 group) of the lysine residue of hemoglobin or the amino group (NH2 group) of the primary amine at the protein terminal, thereby introducing a maleimide group into the amino group (NH2 group) of the lysine residue or the amino group (NH2 group) of the primary amine at the protein terminal. The maleimide group introduction rate into hemoglobin by the maleimide group introduction agent is not particularly limited, but if it is too low, it becomes difficult to form large core particles or a clean core-shell structure of hemoglobin particles, and if it is too high, the hemoglobin is denatured, so it is preferable to appropriately adjust it depending on the purpose and size of the hemoglobin particles. Preferably, 5 to 8 maleimide groups are introduced per hemoglobin molecule.
[0039] Examples of a method for introducing the maleimide group into hemoglobin to obtain maleimide group-introduced hemoglobin include stirring hemoglobin and a maleimide group-introducing agent at 5 to 30° C. for 30 minutes to 24 hours.
[0040] [[Bridge molecules with two or more sulfhydryl groups]] The crosslinking molecule having two or more mercapto groups is not particularly limited as long as it is a molecule that can crosslink (polymerize) maleimide group-introduced hemoglobin, and can be appropriately selected depending on the purpose. A bifunctional compound having mercapto groups at both ends is preferred. Examples of bifunctional compounds having mercapto groups at both ends include dithiothreitol, dithioerythritol, dimercaptosuccinic acid, and compounds having a weight-average molecular weight in the range of 180 to 20,000 daltons, which are represented by the following general formula (4). These may be used alone or in combination of two or more. [ka] (In general formula (4), n represents an integer of 1 to 450.)
[0041] Furthermore, the crosslinking molecule having two or more mercapto groups may be mercapto group-introduced hemoglobin in which two or more mercapto groups have been introduced to lysine on the molecular surface and / or primary amine at the protein terminal. The introduction of mercapto groups can be carried out, for example, by using a mercapto group-introducing agent such as iminothiolane. These may be used alone or in combination of two or more.
[0042] The crosslinking molecule having the two mercapto groups and the maleimide group on the molecular surface of the maleimide-group-introduced hemoglobin form a sulfide bond (covalent bond), thereby crosslinking the hemoglobin molecules together.
[0043] The core fine particle can be obtained, for example, by stirring maleimide group-introduced hemoglobin and a crosslinking molecule having two mercapto groups at 5 to 30° C. for 10 minutes to 12 hours.
[0044] [Shell material] The shell material covers at least a portion of the surface of the core fine particle and includes a plurality of shell molecules having a mercapto group.
[0045] The thickness of the shell material is not particularly limited and may be appropriately adjusted depending on the size and purpose of the hemoglobin microparticles. For example, when serum albumin is used, the thickness of the shell material is about 8 nm. Furthermore, the number of layers of the shell material is not particularly limited, but is preferably 1. With a single layer, crosslinking between shell molecules is unlikely to occur and it is easy to control the coverage of the core microparticles with shell molecules having mercapto groups, which makes it easy to control the particle size and shape of the hemoglobin microparticles. [[Shell molecules with mercapto groups]] The shell molecule having a mercapto group is not particularly limited as long as it is a molecule having a mercapto group, and can be appropriately selected depending on the purpose, and examples thereof include serum albumin, recombinant serum albumin that can be produced by protein synthesis (culture), recombinant serum albumin mutants, etc., synthetic polymers having a mercapto group, such as terminal mercapto-polyethylene glycol, terminal mercapto-polyoxazoline, etc., low molecules having a mercapto group, such as mercaptoethanol, mercapto fatty acid, cysteine, cysteine methyl ester, cysteine ethyl ester, N-acetylcysteine, N-acetylcysteine methyl ester, homocysteine, etc. These may be used alone or in combination of two or more. Among these, serum albumin, mercapto-terminated polyethylene glycol, and mercapto-terminated polyoxazoline are preferred because of their high biocompatibility, and low molecular weight compounds having a mercapto group are preferred because of their low cost. The number of mercapto groups in the shell molecule having the mercapto group is not particularly limited and may be adjusted appropriately depending on the size and purpose of the hemoglobin microparticles, etc., but from the viewpoint of forming a single layer of shell material, it is preferable that there is one mercapto group. Furthermore, the shell molecule having a mercapto group can further bind functional molecules such as drugs depending on the purpose of the hemoglobin microparticles.
[0046] The shell molecule having the mercapto group and the maleimide group on the molecular surface of the maleimide group-introduced hemoglobin of the core microparticle form a sulfide bond (covalent bond), thereby forming a core-shell structure of the hemoglobin microparticle.
[0047] -Serum albumin- The molecular weight of the serum albumin is, for example, about 66,500 daltons. Serum albumin is a simple protein consisting of a single polypeptide chain and has 35 cysteine residues. However, the remaining 34 cysteines, except for the cysteine at the 34th position (cysteine 34), form 17 pairs of disulfide bonds, and therefore only cysteine 34 is active in the reduced form (has a sulfhydryl group).
[0048] The main role of serum albumin in blood is to adjust colloid osmotic pressure, but it also functions as a transport protein for nutrients and their metabolic products (e.g., fatty acids), drugs, etc., and also has pH buffering action, esterase activity, etc. In addition, since serum albumin is a plasma protein, it is extremely advantageous for application to the living body, particularly for use as a red blood cell substitute. The isoelectric point of serum albumin is lower than 7, and under physiological conditions the molecular surface is strongly negatively charged; therefore, due to electrostatic repulsion with the basement membrane (negatively charged) on the outside of vascular endothelial cells, it is unlikely to leak out of blood vessels.
[0049] The serum albumin is not particularly limited and may be selected appropriately according to the purpose, such as one purified from red blood cells derived from vertebrates including humans, and examples thereof include human serum albumin, bovine serum albumin, horse serum albumin, porcine serum albumin, rabbit serum albumin, canine serum albumin, and feline serum albumin. In addition, it may be a recombinant serum albumin or a recombinant serum albumin mutant that can be produced by protein synthesis (culture). These may be used alone or in combination of two or more kinds.
[0050] The mercapto group of the serum albumin and the maleimide group on the surface of the maleimide group-introduced hemoglobin of the core microparticle form a sulfide bond (covalent bond), thereby forming a core-shell structure of the hemoglobin microparticle. The method for binding the serum albumin to the surface of the maleimide group-introduced hemoglobin of the core microparticle includes, for example, stirring at 5 to 30° C. for 1 to 96 hours.
[0051] -Terminated mercapto-polyethylene glycol- Polyethylene glycol (PEG) is a non-ionic water-soluble polymer that can be synthesized by anionic ring-opening polymerization of ethylene oxide, and is widely used in chemical, pharmaceutical, and medical applications. It has a wide range of molecular weights and can be endowed with a wide variety of terminal groups. Polyethylene glycol does not induce an immune response (stealth properties), making it suitable for biological applications. For example, when it is bound to a pharmaceutical product made of protein, it has the effect of inhibiting protein degradation, thereby extending the efficacy of the drug and reducing side effects.
[0052] The terminal mercapto-polyethylene glycol is a polymer obtained by introducing a mercapto group to the terminal of polyethylene glycol. The terminal mercapto-polyethylene glycol is not particularly limited and can be appropriately selected depending on the purpose, and examples thereof include compounds having a weight-average molecular weight in the range of 500 to 100,000 daltons, as represented by the following general formula (5). When the weight-average molecular weight is within the above range, a shell material of appropriate thickness is obtained, so that aggregation of hemoglobin microparticles is unlikely to occur, and problems in metabolism and decomposition tend not to occur. These may be used alone or in combination of two or more. [ka] (In general formula (5), n represents an integer of 9 to 2,270.)
[0053] The mercapto group of the terminal mercapto-polyethylene glycol forms a sulfide bond (covalent bond) with the maleimide group on the molecular surface of the maleimide group-introduced hemoglobin of the core microparticle, thereby forming a core-shell structure of the hemoglobin microparticle. The method for binding the terminal mercapto-polyethylene glycol to the surface of the maleimide group-introduced hemoglobin of the core fine particle includes, for example, stirring at 5 to 30° C. for 1 to 96 hours.
[0054] -Terminated mercapto-polyoxazoline- Polyoxazolines are biocompatible, non-immunogenic, non-ionic, water-soluble polymers with a pseudo-polypeptide structure. They can be synthesized in large quantities, various functional groups can be introduced, and their safety has been confirmed in animal experiments. They exhibit many of the excellent properties of polyethylene glycol while avoiding some of its disadvantages, and are therefore used in pharmacology and medicine. For example, when bound to proteins, liposomes, and micelles, they exhibit the same stealth function as polyethylene glycol, and no disadvantages have been observed in animal models so far. Furthermore, radiolabeling experiments have shown that polyoxazolines are excreted through the kidneys without accumulating in body tissues.
[0055] The terminal mercapto-polyoxazoline is a polymer obtained by introducing a mercapto group to the terminal of polyoxazoline. The terminal mercapto-polyoxazoline is not particularly limited and can be appropriately selected according to the purpose, and examples thereof include compounds having a weight-average molecular weight in the range of 500 to 100,000 daltons, which are represented by the following general formula (6) or (7). When the weight-average molecular weight is within the above range, a shell material of appropriate thickness is obtained, so that aggregation of hemoglobin microparticles is unlikely to occur, and problems in metabolism and decomposition tend not to occur. These may be used alone or in combination of two or more. [ka] (In the general formula (6), n represents an integer of 2 to 1000, m represents an integer of 1 to 10, and R1 represents any one of a methyl group, an ethyl group, a propyl group, and an isopropyl group.) [ka] (In the general formula (7), n represents an integer of 2 to 1000, m represents an integer of 1 to 10, and R1 represents any one of a methyl group, an ethyl group, a propyl group, and an isopropyl group.) Among these, those in which m is 2 and / or R1 is an ethyl group in the following general formula (6) or (7) are preferred.
[0056] The mercapto group of the terminal mercapto-polyoxazoline forms a sulfide bond (covalent bond) with the maleimide group on the molecular surface of the maleimide group-introduced hemoglobin of the core microparticle, thereby forming a core-shell structure of the hemoglobin microparticle. The method for binding the terminal mercapto-polyoxazoline to the surface of the maleimide group-introduced hemoglobin of the core fine particle includes, for example, stirring at 5 to 30° C. for 1 to 96 hours.
[0057] -Small molecule containing mercapto groups- The low molecular weight compound having a mercapto group is not particularly limited and can be appropriately selected according to the purpose, and examples thereof include mercaptoethanol, mercapto fatty acid, cysteine, cysteine methyl ester, cysteine ethyl ester, N-acetylcysteine, N-acetylcysteine methyl ester, and homocysteine. The low molecular weight compound having a mercapto group may have a mercapto group at the end of the low molecular weight compound or at a side branch. These compounds may be used alone or in combination of two or more.
[0058] The mercapto group of the low molecular weight compound having the mercapto group forms a sulfide bond (covalent bond) with the maleimide group on the molecular surface of the maleimide group-introduced hemoglobin of the core particle, thereby forming a core-shell structure of the hemoglobin particle.
[0059] The method for binding the low molecule having a mercapto group to the surface of the maleimide group-introduced hemoglobin of the core fine particle includes, for example, stirring at 5 to 30° C. for 10 minutes to 12 hours.
[0060] [[Other parts]] The other site that is optionally contained in the hemoglobin microparticle of this embodiment is not particularly limited and can be appropriately selected depending on the purpose. For example, a protein bound to hemoglobin can be mentioned.
[0061] The oxygen affinity (P 50 ) (37° C.) is preferably from 3 to 80 Torr, and more preferably from 6 to 35 Torr.
[0062] The hemoglobin microparticles of this embodiment have hemoglobin as the oxygen binding site, and therefore can form stable oxygenated bodies (oxygenated bodies), and can efficiently supply oxygen to body tissues. In addition, the hemoglobin microparticles of this embodiment are covered with a shell material containing a plurality of shell molecules having mercapto groups, and therefore are not immunogenic, are not excreted in the kidney, and are not leaked from vascular endothelial cells. In particular, serum albumin, polyethylene glycol, and polyoxazoline, which can be used as shell molecules having mercapto groups, are highly water-soluble and have excellent metabolic properties. Furthermore, the hemoglobin microparticles of this embodiment are very easy to prepare, for example, with a small number of synthesis steps and column purification steps, and are therefore suitable for mass production. From the above, the hemoglobin microparticles of this embodiment are biocompatible, safe, and easy to produce, and therefore are suitable for application to artificial oxygen carriers.
[0063] [Method of manufacturing hemoglobin microparticles] A method for obtaining the hemoglobin microparticles of this embodiment includes, for example, stirring core microparticles containing a plurality of cross-linked hemoglobins with shell molecules having a mercapto group at 5 to 30° C. for 1 to 96 hours. Fig. 2 is a flow chart showing a method for producing hemoglobin microparticles according to one embodiment of the present invention. The method for producing hemoglobin microparticles 10 in Fig. 2 includes a maleimide group-introduced hemoglobin preparation step of introducing maleimide groups into hemoglobin 1 with a maleimide group-introducing agent to obtain maleimide group-introduced hemoglobin 11, a core microparticle preparation step of crosslinking the maleimide group-introduced hemoglobin 11 with a crosslinking molecule having two or more mercapto groups to prepare core microparticles 2, a crude hemoglobin microparticle preparation step of binding shell molecules 3 having mercapto groups to the core microparticles 2 to prepare crude hemoglobin microparticles, and a purification step of purifying the crude hemoglobin microparticles to obtain hemoglobin microparticles 10.
[0064] <Artificial oxygen carrier> The artificial oxygen carrier of this embodiment is characterized by including the hemoglobin microparticles of the above embodiment. The artificial oxygen carrier is a substance capable of transporting oxygen molecules, and functions as a substitute for red blood cells when administered to a living body. In addition, since the solution of the hemoglobin microparticles of this embodiment does not have colloid osmotic pressure, when used as an artificial oxygen carrier, it may be appropriately mixed with an albumin preparation, a hydroxyethyl starch (HES) preparation, a dextran preparation, etc., in order to bring the colloid osmotic pressure closer to physiological conditions. The artificial oxygen carrier can be used as a substitute for red blood cells of vertebrates such as humans, cows, horses, pigs, rabbits, dogs, and cats. EXAMPLES
[0065] The present invention will be specifically described below based on examples, but the present invention is not limited to these examples.
[0066] Example 1 Human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) [Preparation] In a 50 mL eggplant-shaped flask, 15 mL of purified bovine hemoglobin (HbBv) in phosphate-buffered saline (PBS) (1.0 mM) was added and N-succinimidyl 1.5 mL of a solution (150 mM) of 3-maleimidopropionate (SMP, Mw: 266.21, Fujifilm Wako Pure Chemical Industries, Ltd.) in dimethyl sulfoxide (DMSO) (Fujifilm Wako Pure Chemical Industries, Ltd.) was slowly added dropwise ([SMP] / [HbBv]=15 (mol / mol). During the addition, the HbBv solution was stirred at 250 rpm using a magnetic stirrer. After the addition was completed, a reducing tube was attached to the top of the eggplant-shaped flask, which was then sealed with a septum rubber, and carbon monoxide gas was passed through the flask. The solution was stirred at 200 rpm. The solution was then stirred for an additional 30 minutes at room temperature in the dark. The reaction solution was filtered through a polyethersulfone membrane filter (Millex-GP filter, pore size 0.22 μm, Millipore, hereafter referred to as the "Millex filter"), and the filtrate was subjected to gel filtration chromatography (Sephadex G-25 The unreacted SMP was removed by applying a filter to a Superfine (2.5 cm x 20 cm, flow rate: 3 mL / min, PBS solution). The resulting maleimide group-introduced HbBv (MA-HbBv) solution was adjusted to a constant volume of 45 mL (0.33 mM). 45 mL of MA-HbBv solution was placed in a round-bottom flask (200 mL capacity), and 4.7 mL of a PBS solution (8.3 mM) of dithiothreitol (DTT, Mw: 154.25, Fujifilm Wako Pure Chemical Industries, Ltd.) serving as a crosslinking molecule was slowly dropped ([DTT] / [HbBv] = 2.6 (mol / mol), stirring speed: 250 rpm). The mixture was then stirred for another 20 minutes at room temperature in the dark. 33 μL of this solution and 1.97 mL of PBS were placed in a double-sided quartz cell ([HbBv] = 5 μM), and the particle size was measured by dynamic light scattering (DLS) using a zeta potential, particle size, and molecular weight measurement system (ELSZ-2000ZS, Otsuka Electronics Co., Ltd.). If the particle size was less than 75 nm, PBS solution (8.3 mM) of DTT was dropped again, and the mixture was stirred for 10 minutes at room temperature in the dark, after which the particle size was measured. This procedure was repeated until the particle size reached 75 to 80 nm ([DTT] / [HbBv]=2.8 to 3.00 (mol / mol)). Next, 25.5 mL of a PBS solution (1.76 mM) of human serum albumin (HSA, Nippon Pharmaceutical Co., Ltd., Blood Donation Albumin 25% Intravenous Injection 12.5 g / 50 mL "Nichiyaku") was added dropwise ([HSA] / [HbBv]=3 (mol / mol), stirring speed: 300 rpm). The mixture was stirred at room temperature and in the dark for 72 hours (stirring speed: 250 rpm) to prepare human serum albumin-coated hemoglobin microparticles (HSA-HbBv microparticles).
[0067] [purification] A flat membrane type circulating ultrafiltration (TFF) capsule (Pellicon (registered trademark) XL Cassette, Biomax (registered trademark) 300 kDa, Millipore) was connected to a reservoir and a peristaltic pump (Masterflex, Yamato Scientific), and the human serum albumin-coated hemoglobin microparticles (HSA-HbBv microparticles) (about 75 mL) obtained above were transferred to the reservoir. Unreacted HSA was removed by circulating ultrafiltration (flow rate: 10 mL / min, elution rate: 1 mL / min) for 14 hours under refrigeration and light protection, and the HSA-HbBv microparticles were isolated. The solution was then concentrated to about 10 mL and collected in a measuring cylinder. The HSA-HbBv microparticles in the TFF capsule circuit were collected with a minimum amount (about 10 mL) of PBS solution. The resulting PBS solution of HSA-HbBv microparticles was concentrated to [HbBv] = 6.25 g / dL using a centrifugal ultrafilter (VIVA SPIN, MWCO: 50 kDa). The yield was 75%. 10 μL of the PBS solution of the HSA-HbBv microparticles and 1.99 mL of PBS were placed in a double-sided quartz cell ([HbBv] = 5 μM), and particle size measurement was performed using the DLS method, revealing that the average particle size was approximately 84 nm.
[0068] Example 2 Human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) [Preparation] Human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) were prepared in the same manner as in [Preparation] of Example 1, except that in [Preparation] of Example 1, N-succinimidyl 4-(maleimidomethyl)cyclohexane-1-carboxylate (SMCC, Fujifilm Wako Pure Chemical Industries, Ltd.) was used instead of N-succinimidyl 3-maleimidopropionate (SMP, Fujifilm Wako Pure Chemical Industries, Ltd.) and dithioerythritol (DTE, Fujifilm Wako Pure Chemical Industries, Ltd.) was used instead of dithiothreitol (DTT, Fujifilm Wako Pure Chemical Industries, Ltd.).
[0069] [purification] Human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) were isolated in the same manner as in [Purification] in Example 1, except that the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) obtained in [Preparation] in Example 2 were used instead of the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) obtained in [Preparation] in Example 1. The yield was 74%. The average particle size was measured by DLS method and was found to be approximately 85 nm.
[0070] Example 3 Human serum albumin-coated human hemoglobin microparticles (HSA-HbA microparticles) [Preparation] Human serum albumin-coated human hemoglobin microparticles (HSA-HbA microparticles) were prepared in the same manner as in [Preparation] of Example 1, except that human hemoglobin (HbA) was used instead of bovine hemoglobin (HbBv) in [Preparation] of Example 1.
[0071] [purification] Human serum albumin-coated human hemoglobin microparticles (HSA-HbA microparticles) were isolated in the same manner as in [Purification] in Example 1, except that the human serum albumin-coated human hemoglobin microparticles (HSA-HbA microparticles) obtained in [Preparation] in Example 3 were used instead of the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) obtained in [Preparation] in Example 1. The yield was 78%. The average particle size was measured by DLS method and was found to be approximately 85 nm.
[0072] Example 4 Bovine serum albumin-coated bovine hemoglobin microparticles (BSA-HbBv microparticles) [Preparation] Bovine serum albumin-coated bovine hemoglobin microparticles (BSA-HbBv microparticles) were prepared in the same manner as in [Preparation] of Example 1, except that bovine serum albumin (BSA) was used instead of human serum albumin (HSA) in [Preparation] of Example 1.
[0073] [purification] Bovine serum albumin-coated bovine hemoglobin microparticles (BSA-HbBv microparticles) were isolated in the same manner as in [Purification] in Example 1, except that the bovine serum albumin-coated bovine hemoglobin microparticles (BSA-HbBv microparticles) obtained in [Preparation] in Example 4 were used instead of the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) obtained in [Preparation] in Example 1. The yield was 72%. The average particle size was measured by DLS method and was found to be approximately 85 nm.
[0074] Example 5 Polyethylene glycol-coated bovine hemoglobin microparticles (PEG(5k)-HbBv microparticles) [Preparation] Polyethylene glycol (weight-average molecular weight 5,000 Da)-coated bovine hemoglobin microparticles (PEG(5k)-HbBv microparticles) were prepared in the same manner as in [Preparation] in Example 1, except that in [Preparation] in Example 1, mercapto-terminated polyethylene glycol (weight-average molecular weight 5,000 Da, SH-PEG(5k) (compound of general formula (5))) was used instead of human serum albumin (HSA).
[0075] [purification] Polyethylene glycol (weight average molecular weight 5,000 Da)-coated bovine hemoglobin microparticles (PEG(5k)-HbBv microparticles) obtained in [Preparation] of Example 5 were used instead of the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) obtained in [Preparation] of Example 1, but the same method as in [Purification] of Example 1 was used to isolate bovine hemoglobin microparticles coated with polyethylene glycol (weight average molecular weight 5,000 Da) (PEG(5k)-HbBv microparticles). The yield was 72%. The particle size was measured by DLS method, and the average particle size was found to be about 90 nm.
[0076] Example 6 Polyoxazoline-coated bovine hemoglobin microparticles (POx(5k)-HbBv microparticles) [Preparation] Bovine hemoglobin microparticles (POx(5k)-HbBv microparticles) coated with polyoxazoline (weight average molecular weight 5,000 Da) were prepared in the same manner as in [Preparation] in Example 1, except that in [Preparation] in Example 1, terminal mercapto-polyoxazoline (weight average molecular weight 5,000 Da, SH-POx(5k) (compound of general formula (7) (m = 2)) was used instead of human serum albumin (HSA).
[0077] [purification] Except for using the polyoxazoline (weight average molecular weight 5,000 Da)-coated bovine hemoglobin microparticles (POx(5k)-HbBv microparticles) obtained in [Preparation] of Example 6 instead of the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) obtained in [Preparation] of Example 1, polyoxazoline (weight average molecular weight 5,000 Da)-coated bovine hemoglobin microparticles (POx(5k)-HbBv microparticles) were isolated in the same manner as in [Purification] of Example 1. The yield was 76%. The average particle size was measured by DLS method and was found to be approximately 89 nm.
[0078] Example 7 Polyoxazoline-coated bovine hemoglobin microparticles (POx(10k)-HbBv microparticles) [Preparation] In the [Preparation] of Example 1, bovine hemoglobin microparticles (POx(10k)-HbBv microparticles) coated with polyoxazoline (weight average molecular weight 10,000 Da) were prepared in the same manner as in [Preparation] of Example 1, except that in place of human serum albumin (HSA), terminal mercapto-polyoxazoline (weight average molecular weight 10,000 Da, SH-POx(10k) (compound of general formula (7) (m = 2)) was used.
[0079] [purification] Polyoxazoline (weight average molecular weight 10,000 Da)-coated bovine hemoglobin microparticles (POx(10k)-HbBv microparticles) obtained in [Preparation] of Example 7 were used instead of the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) obtained in [Preparation] of Example 1. Except for this, polyoxazoline (weight average molecular weight 10,000 Da)-coated bovine hemoglobin microparticles (POx(10k)-HbBv microparticles) obtained in [Preparation] of Example 7 were used. Polyoxazoline (weight average molecular weight 10,000 Da)-coated bovine hemoglobin microparticles (POx(10k)-HbBv microparticles) were isolated in the same manner as in [Purification] of Example 1. The yield was 75%. The average particle size was measured by DLS method and was found to be approximately 93 nm.
[0080] Example 8 Polyethylene glycol-coated human hemoglobin microparticles (PEG(5k)-HbA microparticles) [Preparation] Polyethylene glycol (weight-average molecular weight 5,000 Da)-coated human hemoglobin microparticles (PEG(5k)-HbA microparticles) were prepared in the same manner as in [Preparation] in Example 5, except that human hemoglobin (HbA) was used instead of bovine hemoglobin (HbBv) in [Preparation] in Example 5.
[0081] [purification] Polyethylene glycol (weight average molecular weight 5,000 Da)-coated human hemoglobin microparticles (PEG(5k)-HbA microparticles) were isolated in the same manner as in [Purification] in Example 5, except that the polyethylene glycol (weight average molecular weight 5,000 Da)-coated bovine hemoglobin microparticles (PEG(5k)-HbBv microparticles) obtained in [Preparation] in Example 8 were used instead of the polyethylene glycol (weight average molecular weight 5,000 Da)-coated bovine hemoglobin microparticles (PEG(5k)-HbBv microparticles) obtained in [Preparation] in Example 5. The yield was 70%. The average particle size was measured by DLS method and was found to be approximately 86 nm.
[0082] Example 9 Polyoxazoline-coated human hemoglobin microparticles (POx(5k)-HbA microparticles) [Preparation] Pooxazoline (weight average molecular weight 5,000 Da)-coated human hemoglobin microparticles (POx(5k)-HbA microparticles) were prepared in the same manner as in [Preparation] in Example 6, except that human hemoglobin (HbA) was used instead of bovine hemoglobin (HbBv) in [Preparation] in Example 6.
[0083] [purification] Polyoxazoline (weight average molecular weight 5,000 Da)-coated human hemoglobin microparticles (POx(5k)-HbA microparticles) were isolated in the same manner as in [Purification] in Example 6, except that polyoxazoline (weight average molecular weight 5,000 Da)-coated human hemoglobin microparticles (POx(5k)-HbA microparticles) obtained in [Preparation] in Example 9 were used instead of polyoxazoline (weight average molecular weight 5,000 Da)-coated bovine hemoglobin microparticles (POx(5k)-HbBv microparticles) obtained in [Preparation] in Example 6. The yield was 74%. The average particle size was measured by DLS method and was found to be approximately 86 nm.
[0084] Example 10 Polyoxazoline-coated human hemoglobin microparticles (POx(10k)-HbA microparticles) [Preparation] Pooxazoline (weight average molecular weight 10,000 Da)-coated human hemoglobin microparticles (POx(10k)-HbA microparticles) were prepared in the same manner as in [Preparation] in Example 7, except that human hemoglobin (HbA) was used instead of bovine hemoglobin (HbBv) in [Preparation] in Example 7.
[0085] [purification] Polyoxazoline (weight average molecular weight 10,000 Da)-coated human hemoglobin microparticles (POx(10k)-HbA microparticles) were isolated in the same manner as in [Purification] in Example 7, except that polyoxazoline (weight average molecular weight 10,000 Da)-coated human hemoglobin microparticles (POx(10k)-HbA microparticles) obtained in [Preparation] in Example 10 were used instead of polyoxazoline (weight average molecular weight 10,000 Da)-coated bovine hemoglobin microparticles (POx(5k)-HbBv microparticles) obtained in [Preparation] in Example 7. The yield was 79%. The average particle size was measured by DLS method and was found to be approximately 83 nm.
[0086] Example 11 Recombinant canine serum albumin-coated bovine hemoglobin microparticles (rCSA-HbBv microparticles) [Preparation] Recombinant canine serum albumin-coated bovine hemoglobin microparticles (rCSA-HbBv microparticles) were prepared in the same manner as in [Preparation] in Example 1, except that recombinant canine serum albumin (rCSA) was used instead of human serum albumin (HSA) in [Preparation] in Example 1.
[0087] [purification] Recombinant canine serum albumin-coated bovine hemoglobin microparticles (rCSA-HbBv microparticles) were isolated in the same manner as in [Purification] in Example 1, except that the recombinant canine serum albumin-coated bovine hemoglobin microparticles (rCSA-HbBv microparticles) obtained in [Preparation] in Example 11 were used instead of the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) obtained in [Preparation] in Example 1. The yield was 77%. The average particle size was measured by DLS method and was found to be approximately 85 nm.
[0088] Example 12 Recombinant feline serum albumin-coated bovine hemoglobin microparticles (rFSA-HbBv microparticles) [Preparation] Recombinant feline serum albumin-coated bovine hemoglobin microparticles (rFSA-HbBv microparticles) were prepared in the same manner as in [Preparation] in Example 1, except that recombinant feline serum albumin (rFSA) was used instead of human serum albumin (HSA) in [Preparation] in Example 1.
[0089] [purification] Recombinant feline serum albumin-coated bovine hemoglobin microparticles (rFSA-HbBv microparticles) were isolated in the same manner as in [Purification] in Example 1, except that the recombinant feline serum albumin-coated bovine hemoglobin microparticles (rFSA-HBv microparticles) obtained in [Preparation] in Example 12 were used instead of the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) obtained in [Preparation] in Example 1. The yield was 73%. The average particle size was measured by DLS method and was found to be approximately 86 nm.
[0090] Example 13 Human serum albumin-coated bovine hemoglobin (HSA-HbBv (SH-HbBv) microparticles using sulfhydryl-introduced HbBv as a crosslinking agent) [Preparation] A 10 mL solution (1.0 mM) of purified bovine hemoglobin (HbBv) in phosphate buffered saline (PBS) was placed in a 50 mL eggplant-shaped flask, and 1 mL of a 150 mM solution of N-succinimidyl 3-maleimidopropionate (SMP, Mw: 266.21, Fujifilm Wako Pure Chemical Industries, Ltd.) in dimethyl sulfoxide (DMSO) (Fujifilm Wako Pure Chemical Industries, Ltd.) was slowly added dropwise ([SMP] / [HbBv]=15 (mol / mol). During the dropwise addition, the HbBv solution was stirred at 250 rpm using a magnetic stirrer. After the dropwise addition was completed, a reducing tube was attached to the top of the eggplant-shaped flask, which was then sealed with a septum rubber, and carbon monoxide gas was passed through the flask. The solution was stirred at 200 rpm. The mixture was then stirred for an additional 30 minutes at room temperature in the dark. The reaction solution was filtered through a Millex filter, and the filtrate was subjected to gel filtration chromatography (Sephadex G-25 The unreacted SMP was removed by applying a filter to a Superfine (2.5 cm x 20 cm, flow rate: 3 mL / min, PBS solution). The resulting maleimide group-introduced HbBv (MA-HbBv) solution was adjusted to a constant volume of 25 mL (0.40 mM). A 10 mL solution (1.0 mM) of purified bovine hemoglobin (HbBv) in phosphate buffered saline (PBS) was placed in a 50 mL eggplant-shaped flask, and 1 mL of a solution (80 mM) of 2-iminothiolane hydrochloride (IMT, Mw: 137.63, Fujifilm Wako Pure Chemical Industries, Ltd.) in phosphate buffered saline (PBS) was slowly added dropwise ([IMT] / [HbBv]=8 (mol / mol). During the dropwise addition, the HbBv solution was stirred at 250 rpm using a magnetic stirrer. After the dropwise addition was completed, a reducing tube was attached to the top of the eggplant-shaped flask, which was then sealed with a septum rubber, and carbon monoxide gas was passed through the flask. The solution was stirred at 200 rpm. The reaction solution was then stirred for another hour at room temperature in the dark. The reaction solution was filtered through a Millex filter, and the filtrate was subjected to gel filtration chromatography (Sephadex G-25 The unreacted IMT was removed by applying a filter to a Superfine (2.5 cm x 20 cm, flow rate: 3 mL / min, PBS solution). The resulting HbBv solution with mercapto groups introduced (SH-HbBv) was adjusted to a constant volume of 25 mL (0.40 mM). 25 mL of MA-HbBv solution was placed in a recovery flask (200 mL capacity), and 25 mL of a PBS solution (0.40 mM) of SH-HbBv, which serves as a crosslinking molecule, was slowly added dropwise ([SH-HbBv] / [HbBv]=1 (mol / mol), stirring speed: 250 rpm). The mixture was then stirred for an additional 20 minutes at room temperature in the dark. 33 μL of this solution and 1.97 mL of PBS were placed in a double-sided quartz cell ([HbBv]=5 μM), and the particle size was measured by dynamic light scattering (DLS) using a zeta potential, particle size, and molecular weight measurement system (ELSZ-2000ZS, Otsuka Electronics). Next, 25.5 mL of a PBS solution (1.76 mM) of human serum albumin (HSA, Nippon Pharmaceutical Co., Ltd., Blood Donation Albumin 25% Intravenous Injection 12.5 g / 50 mL "Nichiyaku") was added dropwise ([HSA] / [HbBv]=3 (mol / mol), stirring speed: 300 rpm). The mixture was stirred at room temperature and in the dark for 72 hours (stirring speed: 250 rpm) to prepare human serum albumin-coated bovine hemoglobin (using mercapto-introduced HbBv as a crosslinker) microparticles (HSA-HbBv (SH-HbBv) microparticles).
[0091] [purification] Human serum albumin-coated bovine hemoglobin (using mercapto group-introduced HbBv as a crosslinking agent) microparticles (HSA-HbBv (SH-HbBv) microparticles) obtained in [Preparation] of Example 13 were used instead of the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv obtained in [Preparation] of Example 1. The human serum albumin-coated bovine hemoglobin (using mercapto group-introduced HbBv as a crosslinking agent) microparticles (HSA-HbBv (SH-HbBv) microparticles) obtained in [Preparation] of Example 13 were used. The yield was 74%. The average particle size was measured by DLS method and was found to be approximately 84 nm.
[0092] (Oxygen binding capacity measurement) The ultraviolet-visible absorption spectrum of the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) obtained in Example 1 in a phosphate buffered saline (PBS) solution (pH 7.4) in a carbon monoxide atmosphere was λ max The spectral patterns of the carbon monoxide-containing bovine hemoglobin (carbonyl form) were 420 nm, 538 nm, and 569 nm, respectively, which matched the spectral pattern of the carbon monoxide-containing bovine hemoglobin (carbonyl form), indicating that the hemoglobin in the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) had bound carbon monoxide. A solution (pH 7.4) of this human serum albumin-coated bovine hemoglobin microparticle (HSA-HbBv microparticle) in phosphate buffered saline (PBS) is placed in an eggplant-shaped flask, sealed with a septum rubber, and oxygen is aerated while irradiating light. The ultraviolet-visible absorption spectrum is λ max The spectral patterns of the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) were 415 nm, 541 nm, and 577 nm, respectively, which matched the spectral pattern of oxygenated (oxygenated) bovine hemoglobin, indicating that the hemoglobin in the HSA-HbBv microparticles had bound oxygen. Next, when nitrogen is bubbled through a phosphate buffered saline (PBS) solution (pH 7.4) of this hemoglobin microparticle (HSA-HbBv microparticle), the UV-visible absorption spectrum is maxThe spectral patterns of the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) were found to be deoxygenated. The above UV-visible absorption spectrum was measured at 190 nm to 700 nm using a UV-visible spectrophotometer (Agilent, 8454).
[0093] In addition, using an oxygen dissociation binding curve recorder (TSC, Hemox Analyzer), the change in ultraviolet-visible absorption spectrum at different oxygen partial pressures was used to measure the oxygen affinity index P 50 The oxygen partial pressure (oxygen partial pressure at which the oxygen binding rate is 50% in the oxygen dissociation curve graph) was calculated for the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) obtained in Example 1 and the polyethylene glycol-coated bovine hemoglobin microparticles (PEG(5k)-HbBv microparticles) obtained in Example 5. 50 The pressure was 9 Torr (37°C) for all the samples, and the Hill coefficient n, which indicates cooperativity, was 1.4 for all the samples. Figure 3 shows the oxygen dissociation curve, and Table 1 shows the P 50 and the Hill coefficient n are shown. For comparison, the results of measurements of human blood and purified bovine hemoglobin (HbBv) used as the raw material in Examples 1 and 5 are also shown. It was revealed that the oxygen affinity of the hemoglobin microparticles in Examples 1 and 5 was increased compared to the raw material HbBv. Similarly, it was found that other examples also had oxygen binding ability.
[0094] (Stability of hemoglobin particles) A phosphate buffered saline (PBS) solution (pH 7.4) of the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) obtained in Example 1 was stored at 4° C., and particle size measurements were performed by DLS method on days 0, 1, 3, 7, 14, and 28. The measurement results are shown in Figure 4. No change was observed in particle size and particle size dispersibility (PDI) up to 28 days later, demonstrating that the human serum albumin-coated bovine hemoglobin microparticles (HSA-HbBv microparticles) of this example were stable for more than one month. The other examples were also found to be similarly stable.
[0095] [Table 1] [Industrial Applicability]
[0096] The artificial oxygen carrier containing the hemoglobin microparticles of the present invention as an active ingredient can be used as a highly safe red blood cell substitute when administered to a living body. The target is not limited to humans, but the artificial oxygen carrier can also be administered to animals (pets such as dogs and cats, livestock, etc.). In addition, the artificial oxygen carrier containing the hemoglobin microparticles of the present invention as an active ingredient can be expected to be used as a preservation solution or perfusion solution for transplanted organs or tissues, a culture solution for regenerated tissues, an anti-cancer treatment sensitizer for tumors, a preoperative blood dilution solution, a supplement solution for extracorporeal circulation circuits such as a heart-lung machine, an oxygen supply solution for ischemic sites (myocardial infarction, cerebral infarction, respiratory failure, etc.), a chronic anemia treatment agent, and a perfusion solution for liquid ventilation. [Explanation of symbols]
[0097] 10 Hemoglobin Microparticles 1. Hemoglobin 2. Core particles 3. Shell molecules with mercapto groups 4. Shell Material 11 Maleimide-functionalized hemoglobin
Claims
1. Core-shell type hemoglobin particles, The present invention comprises a core particle including a plurality of hemoglobins crosslinked with each other, and a shell material that covers at least a part of the surface of the core particle and includes a plurality of shell molecules having a mercapto group, the shell molecule is bound to the core fine particle via the mercapto group, a maleimide group is introduced onto the molecular surface of the hemoglobin; the hemoglobin is crosslinked via a crosslinking molecule having two or more mercapto groups; the maleimide group of the hemoglobin is bound to the mercapto group of the cross-linking molecule, The shell molecule having a mercapto group includes at least one selected from the group consisting of serum albumin, recombinant serum albumin, recombinant serum albumin mutant, terminal mercapto-polyethylene glycol, and terminal mercapto-polyoxazoline. Hemoglobin microparticles,
2. 2. The hemoglobin microparticle according to claim 1, wherein the site in the hemoglobin to which the maleimide group is introduced is a lysine and / or a primary amine at a protein terminal.
3. the maleimide group of the hemoglobin is derived from a maleimide group-introducing agent, The hemoglobin microparticle according to claim 1 or 2, wherein the maleimide group introducing agent is a bifunctional compound represented by the following general formula (1): 【Chemistry 1】 (In general formula (1), R 2 is a hydrogen atom or SO 3 - Na + represents R 1 represents either the following general formula (2) or (3) or the following chemical formula (1) or (2): 【Chemistry 2】 (In general formula (2), n represents an integer of 1 to 10.) 【Chemistry 3】 【Chemistry 4】 【Chemistry 5】 (In the general formula (3), n represents an integer of 2, 4, 6, 8, 10, or 12.)
4. The hemoglobin microparticle according to any one of claims 1 to 3, wherein the crosslinking molecule having two or more mercapto groups is a bifunctional compound having mercapto groups at both ends.
5. The hemoglobin microparticle according to claim 4, wherein the bifunctional compound having mercapto groups at both ends comprises at least one selected from the group consisting of dithiothreitol, dithioerythritol, dimercaptosuccinic acid, or a compound having a weight average molecular weight in the range of 180 to 20,000 daltons and represented by the following general formula (4): 【Chemistry 6】 (In general formula (4), n represents an integer of 1 to 450.)
6. The hemoglobin microparticle according to any one of claims 1 to 3, wherein the crosslinking molecule having two or more mercapto groups is a mercapto group-introduced hemoglobin in which two or more mercapto groups have been introduced to lysines on the molecular surface and / or primary amines at the protein terminals.
7. The hemoglobin microparticle according to any one of claims 1 to 6, wherein the hemoglobin constituting the core microparticle comprises at least one selected from the group consisting of human hemoglobin, bovine hemoglobin, equine hemoglobin, porcine hemoglobin, rabbit hemoglobin, canine hemoglobin, feline hemoglobin, recombinant hemoglobin, recombinant hemoglobin mutants, and intramolecularly crosslinked hemoglobin.
8. The hemoglobin constituting the core microparticle has a maleimide group introduced into lysine and / or a primary amine at a protein terminal, The hemoglobin microparticle according to any one of claims 1 to 7, wherein the binding site of the core microparticle with the shell molecule having the mercapto group is a maleimide group introduced to the lysine and / or the primary amine at the protein terminal.
9. The hemoglobin microparticle according to any one of claims 1 to 8, wherein the shell molecule having a mercapto group comprises at least one selected from the group consisting of human serum albumin, bovine serum albumin, horse serum albumin, porcine serum albumin, rabbit serum albumin, canine serum albumin, feline serum albumin, recombinant albumin, and recombinant albumin mutants.
10. The hemoglobin microparticle according to any one of claims 1 to 9, wherein the shell molecule having a mercapto group comprises a compound having a weight average molecular weight in the range of 500 to 100,000 daltons and represented by the following general formula (5): 【Chemistry 7】 (In general formula (5), n represents an integer of 9 to 2,270.)
11. The hemoglobin microparticle according to any one of claims 1 to 9, wherein the shell molecule having a mercapto group comprises a compound having a weight average molecular weight in the range of 500 to 100,000 daltons and represented by the following general formula (6): 【Chemistry 8】 (In the general formula (6), n represents an integer of 2 to 1,000, and m represents an integer of 1 to 10. R 1 represents a methyl group, an ethyl group, a propyl group, or an isopropyl group.
12. The hemoglobin microparticle according to any one of claims 1 to 9, wherein the shell molecule having a mercapto group comprises a compound having a weight average molecular weight in the range of 500 to 100,000 daltons and represented by the following general formula (7): 【Chemistry 9】 (In the general formula (7), n represents an integer of 2 to 1,000, and m represents an integer of 1 to 10. R 1 represents a methyl group, an ethyl group, a propyl group, or an isopropyl group.)
13. An artificial oxygen carrier comprising the hemoglobin microparticles according to any one of claims 1 to 12.
Citation Information
Patent Citations
Compact weight training machine
JP1985083674A
Administration of hemoglobin at low dose to increase perfusion
JP1998306036A
Stable Polymerized Hemoglobin Blood Substitute
JP1999502821A
Hemoglobin composition with reduced side effects
JP2003515533A
Pharmaceutical composition containing artificial oxygen transporter
JP2004307404A
